Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.47 |
| ▸ | HSD17B2 | P37059 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | CLK1 | P49759 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5392897 | 0.93 | KMT2A (0.50) | MEN1KMT2AALDH1A1LPAR1HSD17B2 | |
| SCHEMBL5399052 | 0.90 | LPAR1 (0.50) | MEN1KMT2ALPAR1RAB9ALPAR5 | |
| SCHEMBL5409406 | 0.90 | LTB4R (0.48) | MEN1KMT2AALDH1A1RAB9ATSHR | |
| SCHEMBL5394093 | 0.90 | TP53 (0.51) | MEN1KMT2ALPAR1RAB9ALPAR5 | |
| SCHEMBL5402445 | 0.90 | TDP1 (0.52) | MEN1KMT2AALDH1A1LPAR1HSD17B2 | |
| SCHEMBL5401485 | 0.89 | LPAR1 (0.53) | MEN1KMT2ALPAR1RAB9ALPAR5 | |
| SCHEMBL5407116 | 0.89 | ALDH1A1 (0.43) | MEN1KMT2AALDH1A1LPAR1HSD17B2 | |
| SCHEMBL5411801 | 0.88 | LPAR1 (0.54) | LPAR1RAB9ALPAR5TSHR | |
| SCHEMBL5412188 | 0.88 | LPAR1 (0.45) | MEN1KMT2ALPAR1RAB9ALPAR5 | |
| SCHEMBL6232981 | 0.88 | KMT2A (0.60) | MEN1KMT2AALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285680-B2 | β-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-11-17 | — | — | US | disclosed |
| EP-1533294-A1 | BETA-ALANINE DERIVATIVE AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | TGFB1, PML, APOB | MEN1 891/4885KMT2A 2451/4885ALDH1A1 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.